Early intervention facilitated by a digital health application for reporting symptoms of Chronic Obstructive Pulmonary Disease (COPD) provides key benefits for patients, according to the results of a… read more.
Vijayveer Bonthapally et al, Cambridge, MA, USA / by Maria Dalby. AETHERA is a randomised, placebo-controlled phase III study to evaluate whether consolidation treatment with brentuximab vedotin can… read more.
by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).
Dr Graham Collins from the Oxford Cancer and Haematology Centre, Oxford, UK.
Graham Jackson, Professor of Clinical haematology, Newcastle upon Tyne and former president of the British Society for Haematology (BSH). Article by Christine Clark: In the 1970s the prospect… read more.
A faecal microbiota transplant (FMT) not only cured a case of Clostridium difficile (C. diff) infection in a 66 year old man; it eliminated populations of multi-drug resistant organisms both… read more.
by Bruce Sylvester: Researchers from a phase 3, randomized trial of brentuximab vedotin report that adults with hard-to-treat Hodgkin lymphoma treated with brentuximab vedotin immediately after stem cell… read more.
by Thomas R. Collins: Treating patients with T-cell lymphomas is fraught with challenges, requiring new approaches and sharper diagnosis, said Timothy Illidge, MD, PhD, Professor of Targeted Therapy… read more.
by Bruce Sylvester: Treatment of recurrent Clostridium difficile infection with oral, frozen and encapsulated fecal material from unrelated donors has resulted in a 90 percent rate of resolution… read more.
Ger Walpole, CNS (Clinical Nurse Specialist), H.Dip Oncology Nursing, BNS(Hons), Sligo Regional Hospital, Sligo. Dr Andrew Hodgson, MB, BS, BSc (Hons), FRCPI, FFPath, FRCPath. Written by Karen Mas-Mollinedo… read more.
by Bruce Sylvester: Researchers report that 90% of subjects with acute lymphoblastic leukemia (ALL) who had relapsed multiple times or failed to respond to standard therapies have achieved… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
